Why does the management of pharmaceutical companies sell shares?
Five executives of COVID-19 vaccine companies sold several hundred million dollars worth of stock
The news about the sale of shares of such companies as Pfizer, Moderna, Novavax raises questions about the advisability of such a step in the midst of the global health crisis.
The day pharmaceutical giant Pfizer announced preliminary data that the coronavirus vaccine was 90% effective, CEO Albert Burla sold stock worth $5.6 million USD.
According to Pfizer, there was nothing illegal about it: the sale was conducted in accordance with the rules that allow company executives to sell shares according to predetermined criteria, on a certain day or at a predetermined price in order to avoid any suspicion.
In the same pattern, several Moderna executives have sold more than $100 million USD worth of stock in recent months.
This company has not put a product on the market since 2010, but the federal government has pledged to pay it up to $2.5 billion USD if the vaccine proves effective.
One thing that is not clear is why CEOs are selling shares now, when the successful launch of vaccines and the corresponding growth of securities are only months away.
The full article is only available to members of the Immigrant.Today community. Log in to your account to read it for free.
